Pfizer/BioNTech say final results show vaccine 95% effective
An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer and German partner BioNTech, on November 17, 2020.
AFP/JUSTIN TALLIS
Pfizer/BioNTech say final results show vaccine 95% effective
(Agence France-Presse) - November 18, 2020 - 9:19pm

WASHINGTON, United States — Pfizer and BioNTech said Wednesday that a completed study of their experimental Covid-19 vaccine showed it was 95% effective.

They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators "within days."

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," said Pfizer CEO Albert Bourla.

"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," he added.

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on COVID-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2.

Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose.

No mRNA vaccines have ever been approved, but Anthony Fauci, the United States' top infectious disease scientist, told AFP Tuesday the technology had now "established itself."

COVID-19 VACCINES NOVEL CORONAVIRUS PFIZER
As It Happens
LATEST UPDATE: December 1, 2020 - 10:55am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

December 1, 2020 - 10:55am

US President Donald Trump's controversial coronavirus adviser resigned Monday, while hopes for a first wave of vaccinations before the end of 2020 received a further boost with an announcement from US firm Moderna.

Scott Atlas, a favored coronavirus adviser of the US president, who tweeted in October "Masks work? NO," has submitted his resignation, effective as of December 1, Fox News reported.

Lacking relevant experience or qualifications in public health or infectious disease, he also called in November for people in Michigan to "rise up" against COVID-19 measures. — AFP

November 28, 2020 - 1:41pm

A think tank questions the rush to sign a vaccine supply deal with British-Swedish drugmaker AstraZeneca as experts doubt its reported success rate.

“With the new global trials involving the low-dose regimen, it is premature for government to make a supply commitment to AstraZeneca, unless and until there is a showing that the new trials will yield the same ninety-percent efficacy rating in its limited trial run,” says Terry Ridon, Infrawatch PH convenor.

November 28, 2020 - 11:01am

As a string of Covid-19 vaccines near approval, Frankfurt Airport staff are gearing up to handle the unprecedented logistical challenge of transporting millions of life-saving doses worldwide.

Frankfurt is Europe's largest hub for transporting pharmaceutical goods, and will be key to the success of inoculating millions of people against the deadly coronavirus. — AFP

November 27, 2020 - 3:45pm

One of the developers of Russia's Sputnik V coronavirus vaccine announces that India-based drugmaker Hetero will produce over 100 million doses of the jab.

"Hetero, one of India's leading generic pharmaceutical companies, have agreed to produce in India over 100 million doses per year of the world's first registered vaccine against the novel coronavirus infection -– Sputnik V," the Russian Direct Investment Fund says in a statement, adding that production was expected to start in early 2021.

Earlier this week, Russia said interim results from the Sputnik V clinical trails showed the vaccine was 95% effective, similar to other international vaccine makers that have also published test results showing efficacy rates of 90% and higher. — AFP

November 27, 2020 - 11:14am

The World Health Organization urges African countries to improve their capacity to vaccinate populations against COVID-19, warning the continent was still "far from ready" for mass immunisation.

With three coronavirus vaccines now showing efficacy rates of 70% or more, the UN body called on Africa to "ramp up" preparations for "the continent's largest ever immunisation drive".

The African region is so far only 33 percent ready to roll out Covid-19 vaccines, the World Health Organization says in a statement. — AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with